RESUMO
Background: A community COVID-19 outbreak caused by the B.1.1.7 SARS-CoV-2 variant occurred in Taiwan in May 2021. High-risk populations such as people living with HIV (PLWH) were recommended to receive two doses of COVID-19 vaccines. While SARS-CoV-2 vaccines have demonstrated promising results in general population, real-world information on the serological responses remains limited among PLWH. Methods: PLWH receiving the first dose of SARS-CoV-2 vaccine from 2020 to 2021 were enrolled. Determinations of anti-SARS-CoV-2 spike IgG titers were performed every one to three months, the third dose of the SARS-CoV-2 vaccine or confirmed SARS-CoV-2 infection. All serum samples were tested for anti-nucleocapsid antibody and those tested positive were excluded from analysis. Results: A total of 1189 PLWH were enrolled: 829 (69.7%) receiving two doses of the AZD1222 vaccine, 232 (19.5%) of the mRNA-1273 vaccine, and 128 (10.8%) of the BNT162b2 vaccine. At all time-points, PLWH receiving two doses of mRNA vaccines had consistently higher antibody levels than those receiving the AZD1222 vaccine (p <0.001 for all time-point comparisons). Factors associated with failure to achieve an anti-spike IgG titer >141 BAU/mL within 12 weeks, included type 2 diabetes mellitus (DM) (adjusted odds ratio [aOR], 2.24; 95% CI, 1.25-4), a CD4 T cell count <200 cells/mm3 upon receipt of the first dose of vaccination (aOR, 3.43; 95% CI, 1.31-9) and two homologous AZD1222 vaccinations (aOR, 16.85; 95%CI, 10.13-28). For those receiving two doses of mRNA vaccines, factors associated with failure to achieve an anti-spike IgG titer >899 BAU/mL within 12 weeks were a CD4 T cell count <200 cells/mm3 on first-dose vaccination (aOR, 3.95; 95% CI, 1.08-14.42) and dual BNT162b2 vaccination (aOR, 4.21; 95% CI, 2.57-6.89). Conclusions: Two doses of homologous mRNA vaccination achieved significantly higher serological responses than vaccination with AZD1222 among PLWH. Those with CD4 T cell counts <200 cells/mm3 and DM had consistently lower serological responses.
RESUMO
Melatonin is a lipophilic antioxidant generally dissolved in organic solvent before delivery. However, the presence of organics may severely depress the functional effects of melatonin. By rendering deionized water (DIW) flow through gold nano-particles under localized surface plasmon resonant illumination, we developed plasmon-activated water (PAW) which successfully increases the solubility of melatonin to 150.325%. Melatonin dissolved in PAW also exhibits stronger anti-viral and anti-oxidative activities than that dissolved in DIW in which the percentage of dengue virus infected human hepatocellular carcinoma cells is remarkably decreased (14.7% vs. 20.6%) whilst the clearance rate of hydroxyl radical is significantly enhanced (11.9% vs. 6.69%), respectively. Moreover, in vivo approaches further show that following chronic sleep deprivation, the level of oxidative stress, hepatic bioenergetics, anti-oxidative enzyme activity, and metabolic function are all significantly improved in rats received melatonin prepared in PAW than that in DIW. As the bio-activity of melatonin depends largely on its solubility, utilizing PAW as a non-organic solvent will not only enhance the anti-viral and anti-oxidative function of melatonin, but also offer great potential for clinical use of melatonin as a therapeutic strategy to depress virus infection and counteract oxidative damage in a more natural, more economic and more efficient way.